Drug
Rucosopasem manganese clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
Studies by the year they started
3 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
Galera Therapeutics, Inc. (3)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses rucosopasem manganese is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy VolunteersCompletedPhase 1Galera Therapeutics, Inc.NCT03099824Written as GC4711 Oral Capsule G-101
- A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy VolunteersCompletedPhase 1Galera Therapeutics, Inc.NCT03762031Written as GC4711 30mg
- A Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy VolunteersCompletedPhase 1Galera Therapeutics, Inc.NCT03194139Written as GC4711 30 mg IV
Codes
What other systems call rucosopasem manganese · ClinicalTrials.gg INT016600
- UNII (FDA) FW5T90VM32RUCOSOPASEM MANGANESEOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FW5T90VM32 | RUCOSOPASEM MANGANESE | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.